Announcements Trials
Browse Landscape

Status

Completed 4Active not recruiting 1

Sponsor Class

OTHER 13INDUSTRY 5NETWORK 2NIH 1

Study Type

Observational 5

Sponsor

Cancer Type

Genitourinary 5Thoracic 1Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Neoplasms 6Breast Neoplasms 6Prostatic Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Carcinoma, Hepatocellular 3Small Cell Lung Carcinoma 2Lung Neoplasms 2Vulvar Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Trauma, Nervous System 1Thoracic Injuries 1Stomach Neoplasms 1Skin Neoplasms 1Rectal Neoplasms 1Radiculopathy 1Pneumonia 1Pathologic Complete Response 1Papillomavirus Infections 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Melanoma 1Lymphoma 1Lung Diseases, Interstitial 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, B-Cell 1Leukemia 1Laryngeal Neoplasms 1Klippel-Feil Syndrome 1

Interventions

Prednisone 102enzalutamide 74Docetaxel 72Abiraterone Acetate 67Leuprolide 47acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 45abiraterone 37apalutamide 28Prednisolone 27bicalutamide 26Zoledronic Acid 24pembrolizumab 22Goserelin 22radium Ra 223 dichloride 21darolutamide 21Triptorelin Pamoate 17cabazitaxel 15Androgen Antagonists 15sipuleucel-T 13luprolide acetate gel depot 12Injections 12Dexamethasone 12olaparib 11gallium 68 PSMA-11 10Mitoxantrone 10Pluvicto 9Ipilimumab 9Dutasteride 9Cyclophosphamide 9relugolix 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Prostatic Neoplasms × Observation × Clear all
NCT05323747 2025-09-16

BP-008

BioProtect

Completed
20 enrolled
Genitourinary

Prostatic Neoplasms

NCT05354427 2025-09-16

CLP-10095

BioProtect

Completed
175 enrolled
Genitourinary

Prostatic Neoplasms

NCT05179824 2025-05-06

Tempus Priority Study: A Pan-tumor Observational Study

Tempus AI

Active not recruiting
1,000 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmSarcomaThoracic

Bile Duct Neoplasms, Urinary Bladder Neoplasms, Bone Neoplasms, Brain Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Laryngeal Neoplasms, Leukemia, Liver Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Skin Neoplasms, Stomach Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

NCT05423431 2022-06-24

Retrospective Evaluation of a Commercially Available Hydrogel Spacer (BP-009)

BioProtect

Completed
19 enrolled
Genitourinary

Prostatic Neoplasms

NCT00754000 2012-04-30

AIM

Varian, a Siemens Healthineers Company

Completed
82 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡